Tectonic Therapeutic (TECX) FDA Approvals $29.12 +0.60 (+2.10%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$29.16 +0.04 (+0.14%) As of 05/22/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Tectonic Therapeutic's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Tectonic Therapeutic (TECX). Over the past two years, Tectonic Therapeutic has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as TX45. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. TX45 FDA Regulatory Timeline and Events TX45 is a drug developed by Tectonic Therapeutic for the following indication: For the treatment of patients with Group 2 PH-HFpEF. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Top-line results - October 29,2025Top-Line Results Phase 1bDrug: TX45Announced Date: October 29, 2025Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, announced positive topline results from the Phase 1b Part B acute hemodynamic clinical trial of TX45, a long-acting, Fc-relaxin fusion protein, in patients with Group 2 PH‑HFrEF.AI SummaryTectonic Therapeutic announced positive topline results from its Phase 1b Part B acute hemodynamic trial of TX45, a long-acting Fc-relaxin fusion protein, in patients with Group 2 pulmonary hypertension and heart failure with reduced ejection fraction (PH-HFrEF). A single intravenous dose of TX45 was well tolerated, with no serious or severe adverse events, no clinically significant blood pressure changes and no immune-related reactions. TX45 treatment led to meaningful improvements in left heart function and pulmonary hemodynamics. Pulmonary capillary wedge pressure (PCWP) fell by 29.2%, pulmonary vascular resistance (PVR) dropped by nearly 20% in patients with PVR over 3 Wood units, total pulmonary resistance decreased by 29.2%, and mean pulmonary artery pressure fell by 19.3%. Cardiac output rose by 17.3%. Echocardiography at day 29 showed sustained benefits, including a 19.4% increase in left ventricular ejection fraction, 20.3% improvement in right ventricular contractile function, and a 36.3% increase in the TAPSE/SPAP ratio. These results support expanding TX45 into the PH-HFrEF population and guide the ongoing APEX Phase 2 trial.Read AnnouncementResults - May 17,2025Results Phase 1bDrug: TX45Announced Date: May 17, 2025Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic announced the complete results from Part A of the Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), which are being presented in a late-breaking, oral session at the European Society of Cardiology (ESC) Heart Failure 2025 Congress being held in Belgrade, Serbia.AI SummaryTectonic Therapeutic announced the complete results from Part A of its Phase 1b clinical trial of TX45, a long-acting relaxin therapy, in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (PH-HFpEF). The trial, which included 19 patients, showed that TX45 was well tolerated with no serious or severe side effects. The data demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics, including a 19% decrease in pulmonary capillary wedge pressure (PCWP), a key marker linked to exercise capacity and patient outcomes, and significant enhancements in cardiac output. An echocardiographic analysis revealed sustained hemodynamic benefits for up to 29 days after a single TX45 dose, with consistent improvements seen across various left ventricular ejection fraction ranges. These promising results are set to be presented during a late-breaking oral session at the ESC Heart Failure 2025 Congress in Belgrade, Serbia.Read AnnouncementLate Breaking Presentation - April 15,2025Late Breaking Presentation Drug: TX45Announced Date: April 15, 2025Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, announced that it will make a late-breaking oral presentation at the European Society of Cardiology (ESC) Heart Failure 2025 Congress.AI SummaryTectonic Therapeutic recently announced that it will deliver a late-breaking oral presentation at the European Society of Cardiology Heart Failure 2025 Congress in Belgrade, Serbia, from May 17 to 20, 2025. The presentation will focus on Phase 1b clinical data for TX45, the company’s lead asset. TX45 is a long-acting Fc-relaxin fusion protein that shows promise as a best-in-class therapy for patients with Group 2 pulmonary hypertension related to heart failure with preserved ejection fraction (PH-HFpEF). During the session titled “Hemodynamic effects of TX45, a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients,” Dr. Anthony Muslin, Chief Development Officer, will share comprehensive results from the PH-HFpEF cohort. This detailed presentation will provide further insights into TX45’s potential to improve patient outcomes and address this challenging condition.Read AnnouncementPositive Data - January 30,2025Positive Data Phase 1bDrug: TX45Announced Date: January 30, 2025Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, Fc-relaxin fusion protein.AI SummaryTectonic Therapeutic announced positive interim data from its Phase 1b trial of TX45, a long-acting Fc-relaxin fusion protein. In this study focused on patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (PH-HFpEF), a single IV dose of TX45 improved key heart functions. Researchers observed a 17.9% decrease in pulmonary capillary wedge pressure (PCWP), an important measure related to exercise capacity and overall heart health. In patients with the more severe combined pre- and post-capillary PH (CpcPH), TX45 reduced pulmonary vascular resistance (PVR) by over 30%. The treatment was well tolerated, with no serious or severe adverse events noted. These encouraging results support the hemodynamic endpoints targeted in the ongoing APEX Phase 2 trial and offer new hope for patients facing high mortality with few existing treatment options.Read AnnouncementProvided Update - December 3,2024Provided Update Drug: TX45Announced Date: December 3, 2024Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, Inc announced it will host a virtual key opinion leader (KOL) event on Thursday, December 12, 2024 from 4:00 PM to 6:00 PM ET.AI SummaryTectonic Therapeutic, Inc. has announced that it will host a virtual key opinion leader (KOL) event on Thursday, December 12, 2024, from 4:00 PM to 6:00 PM ET. At this online session, distinguished experts, including Dr. John R. Teerlink from UCSF and Dr. Raymond L. Benza from the Icahn School of Medicine at Mount Sinai, will discuss current treatment challenges in Group 2 Pulmonary Hypertension due to heart failure with preserved ejection fraction (HFpEF). The speakers will explore the unmet medical needs of patients in this area and provide insights into Tectonic’s development of TX45, an investigational Fc-relaxin fusion protein designed to activate the RXFP1 receptor. The discussion will highlight TX45’s potential benefits as indicated by ongoing Phase 1b and Phase 2 clinical studies, and a live question and answer session will follow the presentations to engage attendees directly.Read AnnouncementProvided Update - September 19,2024Provided Update Drug: TX45Announced Date: September 19, 2024Target Action Date: Q2 2025Estimated Target Date Range: April 1, 2025 - June 30, 2025Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, announced that Phase 1b single dose hemodynamic proof-of-concept clinical trial in Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF) escalated to the highest dose of TX45 (3 mg/kg) based on favorable tolerability profile observed at lower doses, with topline trial results expected in the second quarter of 2025AI Summary Tectonic Therapeutic announced encouraging progress in its Phase 1b clinical trial for TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF). The single dose hemodynamic proof-of-concept study has now escalated to the highest dose of 3 mg/kg after lower doses were well tolerated with no signs of immunogenicity. Researchers are evaluating TX45’s impact on pulmonary hemodynamics and other safety markers. Topline trial results are expected in the second quarter of 2025, which will help guide dose selection for a planned Phase 2 clinical study. This advancement offers hope for a condition where there are currently no approved treatments, marking a significant step toward potentially improving care for patients with PH-HFpEF. Read AnnouncementTop-line data - September 19,2024Top-Line Data Phase 1aDrug: TX45Announced Date: September 19, 2024Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, announced favorable Phase 1a topline data for its lead asset TX45, a long-acting, potentially best-in-class relaxin. TX45 is being developed for the treatment of Group 2 PH-HFpEF.AI SummaryTectonic Therapeutic announced positive Phase 1a topline results for its lead asset TX45, a long-acting relaxin being developed for treating Group 2 PH-HFpEF. In this early study, TX45 was well-tolerated with no signs of immunogenicity. The trial showed a strong pharmacokinetic and pharmacodynamic (PK/PD) relationship, which helped in selecting the appropriate doses for the upcoming global Phase 2 clinical trial. These results also matched observations from preclinical models, further bolstering confidence in TX45’s potential as a best-in-class therapy. The favorable data supports the continued development of TX45 to address the unmet needs of patients with Group 2 PH-HFpEF, a condition for which there are currently no approved treatments.Read AnnouncementResults - September 19,2024Results Drug: TX45Announced Date: September 19, 2024Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic Results to be presented at the American Heart Association (AHA) Scientific Sessions in November 2024,AI SummaryTectonic Therapeutic, Inc. announced that favorable Phase 1a trial results for its lead program TX45 will be shared at the American Heart Association (AHA) Scientific Sessions in November 2024. TX45, a long-acting fusion protein in development for treating Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF), showed minimal adverse effects and no signs of immune response. These findings demonstrated a strong pharmacokinetic and pharmacodynamic relationship, which helped the company select the appropriate doses for the global Phase 2 clinical trial. The study used both intravenous and subcutaneous doses, with the highest dose of 3 mg/kg well-tolerated in healthy volunteers. Tectonic’s ability to translate preclinical success into the clinic provides a promising path forward for patients with PH-HFpEF, a condition with currently limited treatment options, and the full trial outcomes will be discussed at the upcoming AHA sessions.Read AnnouncementEnrollment Plan - July 30,2024Enrollment Plan Phase 1bDrug: TX45Announced Date: July 30, 2024Target Action Date: H1 2025Estimated Target Date Range: January 1, 2025 - June 30, 2025Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, announced that Phase 1b hemodynamic trial evaluating single doses of TX45 in subjects with Group 2 PH-HFpEF continues to enroll as planned, with topline study results expected in mid-2025AI SummaryTectonic Therapeutic announced that its Phase 1b hemodynamic trial evaluating single doses of TX45 in subjects with Group 2 pulmonary hypertension due to HFpEF is continuing to enroll as planned. Topline study results from this trial are expected to be available by mid-2025. TX45 is an Fc‐relaxin fusion protein being developed to address the unmet needs of patients suffering from this serious condition, which currently has no approved therapies. The trial aims to assess the safety, tolerability, and acute hemodynamic effects of the drug, including its impact on pulmonary and systemic vascular resistance. These efforts build on promising early data and support the continued development of TX45, potentially improving exercise capacity and overall heart function in patients with PH-HFpEF.Read AnnouncementClinical Trial - July 30,2024Clinical Trial Phase 2Drug: TX45Announced Date: July 30, 2024Target Action Date: Q4 2024Estimated Target Date Range: October 1, 2024 - December 31, 2024Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, announced that Planned initiation of global, 24-week Phase 2 clinical trial to evaluate TX45 administered subcutaneously in subjects with Group 2 PH due to HFpEF (PH-HFpEF) in the third quarter of 2024,AI SummaryTectonic Therapeutic announced plans to start a global Phase 2 clinical trial for TX45 in the third quarter of 2024. The study will run for 24 weeks and focus on patients with Group 2 pulmonary hypertension caused by heart failure with preserved ejection fraction (HFpEF). TX45, an Fc-relaxin fusion protein, is designed to improve heart and lung function by promoting vasodilation and reducing cardiac dysfunction. The trial will enroll up to 180 subjects who will receive TX45 by subcutaneous injection, compared with a placebo group. Researchers hope that the treatment will lead to better exercise capacity and improved pulmonary and systemic hemodynamics in these patients. Topline results from this study are expected by 2026, potentially offering a new therapeutic option for the more than 600,000 patients in the U.S. affected by this serious condition.Read AnnouncementTop-line results - July 30,2024Top-Line Results Phase 1aDrug: TX45Announced Date: July 30, 2024Target Action Date: September 1, 2024Estimated Target Date Range: September 1, 2024 - September 30, 2024Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, announced that Phase 1a topline trial results of TX45 in healthy volunteers are expected to be released this September, with detailed data to be subsequently presented at a scientific meetingAI SummaryTectonic Therapeutic announced promising news regarding its experimental treatment, TX45, an Fc-relaxin fusion protein designed to treat Group 2 pulmonary hypertension (PH) caused by heart failure with preserved ejection fraction (HFpEF). The company expects to release the topline results from its Phase 1a clinical trial in healthy volunteers this September. Following this initial report, more detailed data will be presented at a scientific meeting, offering further insights into the safety, pharmacokinetics, and pharmacodynamics of TX45. This early phase study is an important step in the drug’s development, as TX45 is engineered to potentially improve both pulmonary and systemic vasodilation, as well as cardiac function. The results will also help guide future research and the design of upcoming trials, moving closer to addressing the significant unmet medical need for effective treatments among patients with PH-HFpEF in the U.S.Read AnnouncementFDA Clearance - July 30,2024Fda Clearance INDDrug: TX45Announced Date: July 30, 2024Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, nnounced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for TX45, an Fc-relaxin fusion protein being evaluated for the treatment of patients with Group 2 PH-HFpEF.AI SummaryTectonic Therapeutic announced that the FDA has cleared its Investigational New Drug (IND) application for TX45, an Fc-relaxin fusion protein being developed to treat patients with Group 2 Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction (PH-HFpEF). TX45 is designed to improve blood flow by promoting vasodilation in the lungs and the rest of the body and may help improve heart function by addressing diastolic dysfunction and potentially remodeling both pulmonary vessels and cardiac muscle. The clearance supports the company’s plan to start a global, 24-week Phase 2 clinical trial in the third quarter of 2024, which will assess the drug’s effectiveness in a large group of PH-HFpEF patients. Early clinical studies in healthy volunteers and patients are also underway to evaluate safety and pharmacologic responses, with further results expected in the coming years.Read AnnouncementTop-line results - July 30,2024Top-Line Results Phase 2Drug: TX45Announced Date: July 30, 2024Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, announced that topline trial results expected in 2026AI SummaryTectonic Therapeutic announced that it expects topline results from its global Phase 2 clinical trial in 2026. The trial is designed to evaluate TX45, an Fc-relaxin fusion protein for treating patients with Group 2 Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction (HFpEF). The study will last for 24 weeks, during which patients will receive TX45 via subcutaneous injections. Up to 180 patients, including a subgroup with a more severe form of the disease, will be enrolled to examine changes in pulmonary vascular resistance and other hemodynamic endpoints, as well as improvements in exercise capacity measured by the six-minute walk distance. The announcement highlights the company’s commitment to addressing the unmet needs of patients with PH-HFpEF. Prior trial plans include additional studies to assess TX45’s safety and initial efficacy, further supporting the potential of this novel therapeutic approach.Read Announcement Tectonic Therapeutic FDA Events - Frequently Asked Questions Has Tectonic Therapeutic received FDA approval? As of now, Tectonic Therapeutic (TECX) has not received any FDA approvals for its therapy in the last two years. What drugs has Tectonic Therapeutic submitted to the FDA? In the past two years, Tectonic Therapeutic (TECX) has reported FDA regulatory activity for TX45. What is the most recent FDA event for Tectonic Therapeutic? The most recent FDA-related event for Tectonic Therapeutic occurred on October 29, 2025, involving TX45. The update was categorized as "Top-line results," with the company reporting: "Tectonic Therapeutic, announced positive topline results from the Phase 1b Part B acute hemodynamic clinical trial of TX45, a long-acting, Fc-relaxin fusion protein, in patients with Group 2 PH‑HFrEF." What conditions do Tectonic Therapeutic's current drugs treat? Currently, Tectonic Therapeutic has one therapy (TX45) targeting the following condition: For the treatment of patients with Group 2 PH-HFpEF.. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events AC Immune FDA EventsAgios Pharmaceuticals FDA EventsAssembly Biosciences FDA EventsBriacell Therap FDA EventsBioLineRx FDA EventsFibroBiologics FDA EventsGilead Sciences FDA EventsOncolytics Biotech FDA EventsRegeneron Pharmaceuticals FDA EventsAbbVie FDA EventsMerck & Co., Inc. FDA EventsAgenus FDA EventsAdagio Medical FDA EventsAktis Oncology FDA EventsAkari Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies HUTCHMED FDA Events Adaptive Biotechnologies FDA Events Aurinia Pharmaceuticals FDA Events Bausch Health Cos FDA Events Trevi Therapeutics FDA Events Mesoblast FDA Events Pharvaris FDA Events Ocular Therapeutix FDA Events Stoke Therapeutics FDA Events ANI Pharmaceuticals FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:TECX last updated on 10/29/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredA 25,000% opportunityAngel investor Jason Calacanis - who made a fortune on an early Uber stake - says Elon Musk's latest project c...The Oxford Club | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredThis small stock could surge when SpaceX goes publicWhen SpaceX goes public, billions in capital won't just flow into one stock - it will flood the entire sector....NXT Wave Research | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tectonic Therapeutic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tectonic Therapeutic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Top-line results - October 29,2025Top-Line Results Phase 1bDrug: TX45Announced Date: October 29, 2025Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, announced positive topline results from the Phase 1b Part B acute hemodynamic clinical trial of TX45, a long-acting, Fc-relaxin fusion protein, in patients with Group 2 PH‑HFrEF.AI SummaryTectonic Therapeutic announced positive topline results from its Phase 1b Part B acute hemodynamic trial of TX45, a long-acting Fc-relaxin fusion protein, in patients with Group 2 pulmonary hypertension and heart failure with reduced ejection fraction (PH-HFrEF). A single intravenous dose of TX45 was well tolerated, with no serious or severe adverse events, no clinically significant blood pressure changes and no immune-related reactions. TX45 treatment led to meaningful improvements in left heart function and pulmonary hemodynamics. Pulmonary capillary wedge pressure (PCWP) fell by 29.2%, pulmonary vascular resistance (PVR) dropped by nearly 20% in patients with PVR over 3 Wood units, total pulmonary resistance decreased by 29.2%, and mean pulmonary artery pressure fell by 19.3%. Cardiac output rose by 17.3%. Echocardiography at day 29 showed sustained benefits, including a 19.4% increase in left ventricular ejection fraction, 20.3% improvement in right ventricular contractile function, and a 36.3% increase in the TAPSE/SPAP ratio. These results support expanding TX45 into the PH-HFrEF population and guide the ongoing APEX Phase 2 trial.Read Announcement
Results - May 17,2025Results Phase 1bDrug: TX45Announced Date: May 17, 2025Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic announced the complete results from Part A of the Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), which are being presented in a late-breaking, oral session at the European Society of Cardiology (ESC) Heart Failure 2025 Congress being held in Belgrade, Serbia.AI SummaryTectonic Therapeutic announced the complete results from Part A of its Phase 1b clinical trial of TX45, a long-acting relaxin therapy, in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (PH-HFpEF). The trial, which included 19 patients, showed that TX45 was well tolerated with no serious or severe side effects. The data demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics, including a 19% decrease in pulmonary capillary wedge pressure (PCWP), a key marker linked to exercise capacity and patient outcomes, and significant enhancements in cardiac output. An echocardiographic analysis revealed sustained hemodynamic benefits for up to 29 days after a single TX45 dose, with consistent improvements seen across various left ventricular ejection fraction ranges. These promising results are set to be presented during a late-breaking oral session at the ESC Heart Failure 2025 Congress in Belgrade, Serbia.Read Announcement
Late Breaking Presentation - April 15,2025Late Breaking Presentation Drug: TX45Announced Date: April 15, 2025Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, announced that it will make a late-breaking oral presentation at the European Society of Cardiology (ESC) Heart Failure 2025 Congress.AI SummaryTectonic Therapeutic recently announced that it will deliver a late-breaking oral presentation at the European Society of Cardiology Heart Failure 2025 Congress in Belgrade, Serbia, from May 17 to 20, 2025. The presentation will focus on Phase 1b clinical data for TX45, the company’s lead asset. TX45 is a long-acting Fc-relaxin fusion protein that shows promise as a best-in-class therapy for patients with Group 2 pulmonary hypertension related to heart failure with preserved ejection fraction (PH-HFpEF). During the session titled “Hemodynamic effects of TX45, a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients,” Dr. Anthony Muslin, Chief Development Officer, will share comprehensive results from the PH-HFpEF cohort. This detailed presentation will provide further insights into TX45’s potential to improve patient outcomes and address this challenging condition.Read Announcement
Positive Data - January 30,2025Positive Data Phase 1bDrug: TX45Announced Date: January 30, 2025Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, Fc-relaxin fusion protein.AI SummaryTectonic Therapeutic announced positive interim data from its Phase 1b trial of TX45, a long-acting Fc-relaxin fusion protein. In this study focused on patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (PH-HFpEF), a single IV dose of TX45 improved key heart functions. Researchers observed a 17.9% decrease in pulmonary capillary wedge pressure (PCWP), an important measure related to exercise capacity and overall heart health. In patients with the more severe combined pre- and post-capillary PH (CpcPH), TX45 reduced pulmonary vascular resistance (PVR) by over 30%. The treatment was well tolerated, with no serious or severe adverse events noted. These encouraging results support the hemodynamic endpoints targeted in the ongoing APEX Phase 2 trial and offer new hope for patients facing high mortality with few existing treatment options.Read Announcement
Provided Update - December 3,2024Provided Update Drug: TX45Announced Date: December 3, 2024Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, Inc announced it will host a virtual key opinion leader (KOL) event on Thursday, December 12, 2024 from 4:00 PM to 6:00 PM ET.AI SummaryTectonic Therapeutic, Inc. has announced that it will host a virtual key opinion leader (KOL) event on Thursday, December 12, 2024, from 4:00 PM to 6:00 PM ET. At this online session, distinguished experts, including Dr. John R. Teerlink from UCSF and Dr. Raymond L. Benza from the Icahn School of Medicine at Mount Sinai, will discuss current treatment challenges in Group 2 Pulmonary Hypertension due to heart failure with preserved ejection fraction (HFpEF). The speakers will explore the unmet medical needs of patients in this area and provide insights into Tectonic’s development of TX45, an investigational Fc-relaxin fusion protein designed to activate the RXFP1 receptor. The discussion will highlight TX45’s potential benefits as indicated by ongoing Phase 1b and Phase 2 clinical studies, and a live question and answer session will follow the presentations to engage attendees directly.Read Announcement
Provided Update - September 19,2024Provided Update Drug: TX45Announced Date: September 19, 2024Target Action Date: Q2 2025Estimated Target Date Range: April 1, 2025 - June 30, 2025Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, announced that Phase 1b single dose hemodynamic proof-of-concept clinical trial in Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF) escalated to the highest dose of TX45 (3 mg/kg) based on favorable tolerability profile observed at lower doses, with topline trial results expected in the second quarter of 2025AI Summary Tectonic Therapeutic announced encouraging progress in its Phase 1b clinical trial for TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF). The single dose hemodynamic proof-of-concept study has now escalated to the highest dose of 3 mg/kg after lower doses were well tolerated with no signs of immunogenicity. Researchers are evaluating TX45’s impact on pulmonary hemodynamics and other safety markers. Topline trial results are expected in the second quarter of 2025, which will help guide dose selection for a planned Phase 2 clinical study. This advancement offers hope for a condition where there are currently no approved treatments, marking a significant step toward potentially improving care for patients with PH-HFpEF. Read Announcement
Top-line data - September 19,2024Top-Line Data Phase 1aDrug: TX45Announced Date: September 19, 2024Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, announced favorable Phase 1a topline data for its lead asset TX45, a long-acting, potentially best-in-class relaxin. TX45 is being developed for the treatment of Group 2 PH-HFpEF.AI SummaryTectonic Therapeutic announced positive Phase 1a topline results for its lead asset TX45, a long-acting relaxin being developed for treating Group 2 PH-HFpEF. In this early study, TX45 was well-tolerated with no signs of immunogenicity. The trial showed a strong pharmacokinetic and pharmacodynamic (PK/PD) relationship, which helped in selecting the appropriate doses for the upcoming global Phase 2 clinical trial. These results also matched observations from preclinical models, further bolstering confidence in TX45’s potential as a best-in-class therapy. The favorable data supports the continued development of TX45 to address the unmet needs of patients with Group 2 PH-HFpEF, a condition for which there are currently no approved treatments.Read Announcement
Results - September 19,2024Results Drug: TX45Announced Date: September 19, 2024Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic Results to be presented at the American Heart Association (AHA) Scientific Sessions in November 2024,AI SummaryTectonic Therapeutic, Inc. announced that favorable Phase 1a trial results for its lead program TX45 will be shared at the American Heart Association (AHA) Scientific Sessions in November 2024. TX45, a long-acting fusion protein in development for treating Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF), showed minimal adverse effects and no signs of immune response. These findings demonstrated a strong pharmacokinetic and pharmacodynamic relationship, which helped the company select the appropriate doses for the global Phase 2 clinical trial. The study used both intravenous and subcutaneous doses, with the highest dose of 3 mg/kg well-tolerated in healthy volunteers. Tectonic’s ability to translate preclinical success into the clinic provides a promising path forward for patients with PH-HFpEF, a condition with currently limited treatment options, and the full trial outcomes will be discussed at the upcoming AHA sessions.Read Announcement
Enrollment Plan - July 30,2024Enrollment Plan Phase 1bDrug: TX45Announced Date: July 30, 2024Target Action Date: H1 2025Estimated Target Date Range: January 1, 2025 - June 30, 2025Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, announced that Phase 1b hemodynamic trial evaluating single doses of TX45 in subjects with Group 2 PH-HFpEF continues to enroll as planned, with topline study results expected in mid-2025AI SummaryTectonic Therapeutic announced that its Phase 1b hemodynamic trial evaluating single doses of TX45 in subjects with Group 2 pulmonary hypertension due to HFpEF is continuing to enroll as planned. Topline study results from this trial are expected to be available by mid-2025. TX45 is an Fc‐relaxin fusion protein being developed to address the unmet needs of patients suffering from this serious condition, which currently has no approved therapies. The trial aims to assess the safety, tolerability, and acute hemodynamic effects of the drug, including its impact on pulmonary and systemic vascular resistance. These efforts build on promising early data and support the continued development of TX45, potentially improving exercise capacity and overall heart function in patients with PH-HFpEF.Read Announcement
Clinical Trial - July 30,2024Clinical Trial Phase 2Drug: TX45Announced Date: July 30, 2024Target Action Date: Q4 2024Estimated Target Date Range: October 1, 2024 - December 31, 2024Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, announced that Planned initiation of global, 24-week Phase 2 clinical trial to evaluate TX45 administered subcutaneously in subjects with Group 2 PH due to HFpEF (PH-HFpEF) in the third quarter of 2024,AI SummaryTectonic Therapeutic announced plans to start a global Phase 2 clinical trial for TX45 in the third quarter of 2024. The study will run for 24 weeks and focus on patients with Group 2 pulmonary hypertension caused by heart failure with preserved ejection fraction (HFpEF). TX45, an Fc-relaxin fusion protein, is designed to improve heart and lung function by promoting vasodilation and reducing cardiac dysfunction. The trial will enroll up to 180 subjects who will receive TX45 by subcutaneous injection, compared with a placebo group. Researchers hope that the treatment will lead to better exercise capacity and improved pulmonary and systemic hemodynamics in these patients. Topline results from this study are expected by 2026, potentially offering a new therapeutic option for the more than 600,000 patients in the U.S. affected by this serious condition.Read Announcement
Top-line results - July 30,2024Top-Line Results Phase 1aDrug: TX45Announced Date: July 30, 2024Target Action Date: September 1, 2024Estimated Target Date Range: September 1, 2024 - September 30, 2024Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, announced that Phase 1a topline trial results of TX45 in healthy volunteers are expected to be released this September, with detailed data to be subsequently presented at a scientific meetingAI SummaryTectonic Therapeutic announced promising news regarding its experimental treatment, TX45, an Fc-relaxin fusion protein designed to treat Group 2 pulmonary hypertension (PH) caused by heart failure with preserved ejection fraction (HFpEF). The company expects to release the topline results from its Phase 1a clinical trial in healthy volunteers this September. Following this initial report, more detailed data will be presented at a scientific meeting, offering further insights into the safety, pharmacokinetics, and pharmacodynamics of TX45. This early phase study is an important step in the drug’s development, as TX45 is engineered to potentially improve both pulmonary and systemic vasodilation, as well as cardiac function. The results will also help guide future research and the design of upcoming trials, moving closer to addressing the significant unmet medical need for effective treatments among patients with PH-HFpEF in the U.S.Read Announcement
FDA Clearance - July 30,2024Fda Clearance INDDrug: TX45Announced Date: July 30, 2024Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, nnounced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for TX45, an Fc-relaxin fusion protein being evaluated for the treatment of patients with Group 2 PH-HFpEF.AI SummaryTectonic Therapeutic announced that the FDA has cleared its Investigational New Drug (IND) application for TX45, an Fc-relaxin fusion protein being developed to treat patients with Group 2 Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction (PH-HFpEF). TX45 is designed to improve blood flow by promoting vasodilation in the lungs and the rest of the body and may help improve heart function by addressing diastolic dysfunction and potentially remodeling both pulmonary vessels and cardiac muscle. The clearance supports the company’s plan to start a global, 24-week Phase 2 clinical trial in the third quarter of 2024, which will assess the drug’s effectiveness in a large group of PH-HFpEF patients. Early clinical studies in healthy volunteers and patients are also underway to evaluate safety and pharmacologic responses, with further results expected in the coming years.Read Announcement
Top-line results - July 30,2024Top-Line Results Phase 2Drug: TX45Announced Date: July 30, 2024Indication: For the treatment of patients with Group 2 PH-HFpEF. AnnouncementTectonic Therapeutic, announced that topline trial results expected in 2026AI SummaryTectonic Therapeutic announced that it expects topline results from its global Phase 2 clinical trial in 2026. The trial is designed to evaluate TX45, an Fc-relaxin fusion protein for treating patients with Group 2 Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction (HFpEF). The study will last for 24 weeks, during which patients will receive TX45 via subcutaneous injections. Up to 180 patients, including a subgroup with a more severe form of the disease, will be enrolled to examine changes in pulmonary vascular resistance and other hemodynamic endpoints, as well as improvements in exercise capacity measured by the six-minute walk distance. The announcement highlights the company’s commitment to addressing the unmet needs of patients with PH-HFpEF. Prior trial plans include additional studies to assess TX45’s safety and initial efficacy, further supporting the potential of this novel therapeutic approach.Read Announcement
